The difference in the CAIX plasma level may reflect distinct molecular pathways and genetic alterations that impact small-sized tumours, which may determine the subsequent development and risk of progression, as already suggested for bladder cancers (Turner et al, 2002). Here, CA9 is linked to neoplasm.